Advanced Center for Continuous Glucose Monitoring Sensor Production Opens in Ireland
Pharmaceutical company Abbott has inaugurated an advanced manufacturing facility in Kilkenny, Ireland, marking a milestone in global diabetes care.
Spanning 30,000 square meters, this facility will serve as the production hub for FreeStyle Libre 3 sensors, the smallest and most advanced continuous glucose monitoring (CGM) sensors in the world.
This center is part of Abbott’s €440 million investment in Ireland and will employ over 800 people, becoming a cornerstone of Abbott’s operations in the country.
FreeStyle Libre 3 sensors, the world’s smallest of their kind, adhere to the back of a diabetic patient’s arm and eliminate the daily need for multiple finger-prick glucose tests.
According to Robert Ford, CEO of Abbott, approximately six million people across more than 60 countries use FreeStyle Libre continuous glucose monitoring systems.
End of Message
Feel free to share this content with attribution to The World of Health and Medicine.
